This query is part of ongoing active monitoring activities for ibrexafungerp. Ibrexafungerp is an antifungal agent used to treat vulvovaginal candidiasis (VVC) in post‐menarchal women and is contraindicated for use in pregnancy due to findings of severe fetal toxicity. This query aims to identify early signaling of ibrexafungerp use in pregnant patients.
The study period includes data from June 1, 2020 to May 26, 2022 and contains data from 74 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network. We ran this query on June 23, 2022.